"We are thankfully starting to be blessed with more options than we ve ever had," but "in the frontline proliferative setting, ruxolitinib has remained the standard of care."
The study raises the possibility of one day treating the immune system in some individuals for the prevention and treatment of cardiovascular disease, researchers suggest.
The results add to current understanding of the role of different biomarkers in treatment response, in this population, according to the lead study author.
This drug is the first BTK inhibitor approved to treat mantle cell lymphoma in this setting. Approval was based on overall response rates and duration of response in the phase 1/2 BRUIN trial.